Date: 15 April 2023

Your Name: Mario Uccello

Manuscript Title: Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence

Manuscript number (if known): APM-22-1350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined</u> <u>broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	X_None			
5	Payment or honoraria for	X_None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or educational events				
6	Payment for expert	X_None			
0	testimony	XNone			
	testimony				
7	Support for attending	X None			
•	meetings and/or travel	XNone			
8	Patents planned, issued	X None			
	or pending	XNone			
9	Participation on a Data	X None			
	Safety Monitoring Board or Advisory Board				
10	Leadership or fiduciary role in other board, society, committee or	_XNone			
	advocacy group, paid or				
	unpaid				
11	Stock or stock options	X_None			
12	Receipt of equipment,	XNone			
12	materials, drugs, medical	X_None			
	writing, gifts or other				
	services				
13	Other financial or non-	_XNone			
	financial interests				
Ple	ease summarize the abo	ve conflict of interest in	the following box:		

have no conflict of interest.	

X I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: 15 April 2023

Your Name: Sola Adeleke

Manuscript Title: Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence

Manuscript number (if known): APM-22-1350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined</u> <u>broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	_XNone	

	in item #1 above).		
3	Royalties or licenses	_XNone	
	1.0 yailioo or noonsos	_/\NONE	
4	Consulting fees	X None	
	Consuming ices	_XNone	
5	Payment or honoraria for	X None	
	lectures, presentations,	XNOTIC	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	_XNone	
	Ğ		
8	Patents planned, issued	XNone	
	or pending		
9	Participation on a Data	X_None	
9	Safety Monitoring Board	XNone	
	or Advisory Board		
10	Leadership or fiduciary	_XNone	
	role in other board,	XNone	
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	_XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X_None	
	financial interests		

Please summarize the above conflict of interest in the following box:

I have no conflict of interest.		

X I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: 15 April 2023

Your Name: Michele Moschetta

Manuscript Title: Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence

Manuscript number (if known): APM-22-1350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined</u> <u>broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	_XNone	

	in item #1 above).		
3	Royalties or licenses	X None	
4	Consulting fees	_XNone	
5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events Payment for expert	V Name	
6	testimony	_XNone	
	testimony		
7	Support for attending	X None	
′	meetings and/or travel	XNone	
	modaligo ana, or travor		
8	Patents planned, issued	Author of a patent	
0	or pending	planned for the	
	or penamy	development of the	
		drug LXH254,	
		naporafenib	
9	Participation on a Data	_XNone	
	Safety Monitoring Board		
	or Advisory Board		
10	Leadership or fiduciary	_XNone	
	role in other board,		
	society, committee or		
	advocacy group, paid or unpaid		
11	Stock or stock options	Novartis shareholder	
' '	Clock of Glock options	1 10 Val tio Silai Gilolagi	
12	Receipt of equipment,	_XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	Novartis full time	
	financial interests	employee	

Please summarize the above conflict of interest in the following box:

Michele Moschetta is a full-time Novartis employee and Novartis shareholder. Michele Moschetta declares no relevant conflict of interest related to this work.

X I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: 11 April 2023

Your Name: Aruni Ghose

Manuscript Title: Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence

Manuscript number (if known): APM-22-1350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined</u> <u>broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_XNone	
3	Royalties or licenses	_XNone	

	0 111 6			
4	Consulting fees	_XNone		
_				
5	Payment or honoraria for	_XNone		
	lectures, presentations, speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	X None		
	testimony			
	,			
7	Support for attending	X None		
	meetings and/or travel			
8	Patents planned, issued or pending	X None		
9	Participation on a Data Safety Monitoring Board	_XNone		
	or Advisory Board			
10	Leadership or fiduciary	X_None		
	role in other board,			
	society, committee or			
	advocacy group, paid or unpaid			
11	Stock or stock options	X None		
	Clock of Glock options	XNone		
12	Receipt of equipment,	_XNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
יום		الماد والمالية المالية والمالية والمالية	the fellowing boy.	
716	Please summarize the above conflict of interest in the following box:			

I have no conflict of interest.		

X I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: 11 April 2023

Your Name: Stergios Boussios

Manuscript Title: Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence

Manuscript number (if known): APM-22-1350

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined</u> <u>broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Ti	me frame: Since the initia	I planning of the work
1	All support for the	XNone	
	present manuscript (e.g.,		
	funding, provision of		
	study materials, medical		
	vriting, article processing		
	charges, etc.)		
	No time limit for this item.		
	item.		
		Time frame: past	36 months
2	Grants or contracts from	X_None	
	any entity (if not indicated		
	in item #1 above).		

3	Royalties or licenses	_XNone
4	Consulting fees	X_None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	X_None
8	Patents planned, issued or pending	_XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_XNone
11	Stock or stock options	_XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_XNone
13	Other financial or non- financial interests	X_None

Please summarize the above conflict of interest in the following box:

I have no conflict of interest.				

X I certify that I have answered every question and have not altered the wording of any of the questions on this